help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doring, G.
Right arrow Articles by Dorner, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doring, G.
Right arrow Articles by Dorner, F.

Am. J. Respir. Crit. Care Med., Vol 151, No. 4, Apr 1995, 983-985.

Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals

G Doring, C Pfeiffer, U Weber, A Mohr-Pennert and F Dorner
Department of General and Environmental Hygiene, University of Tubingen, Germany.

To test the hypothesis that a Pseudomonas aeruginosa flagella (FLA) vaccine, intramuscularly administered, elicits specific antibodies in the respiratory tract, antibody titers against FLA were determined in sera and bronchoalveolar lavage (BAL) fluids of 10 healthy human adults before and after immunization. Immunization produced significantly increased anti-FLA antibody titers in all sera (mean reciprocal titers: IgG: 26,711; IgA: 2,767; IgM: 421) and on respiratory epithelial lining fluids (mean reciprocal titers: IgG: 112; IgA: 76; sIgA: 26). Significant differences in class-specific serum and BAL anti-FLA titers suggested airway antibody production. The study shows that parenteral immunization provides not only high systemic antibody titers but also local antibody production in the human respiratory tract.


This article has been cited by other articles:


Home page
AAP Grand RoundsHome page
M. Dubik and L. L. Barton
Pseudomonas Vaccine for Cystic Fibrosis: A Work in Progress
AAP Grand Rounds, October 1, 2007; 18(4): 39 - 40.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Doring, C. Meisner, M. Stern, and for the Flagella Vaccine Trial Study Group
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients
PNAS, June 26, 2007; 104(26): 11020 - 11025.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
G. P. Priebe, G. J. Meluleni, F. T. Coleman, J. B. Goldberg, and G. B. Pier
Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant
Infect. Immun., March 1, 2003; 71(3): 1453 - 1461.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. M. P. T. Herremans, J. H. J. Reimerink, A. M. Buisman, T. G. Kimman, and M. P. G. Koopmans
Induction of Mucosal Immunity by Inactivated Poliovirus Vaccine Is Dependent on Previous Mucosal Contact with Live Virus
J. Immunol., April 15, 1999; 162(8): 5011 - 5018.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1995 American Thoracic Society